Furthermore, 89Zr-GSK2849330 uptake in tumor and the normalized tumor to blood ratios at 144 hours post injection of 89Zr-GSK2849330 were clearly differentiated between the HER3 expressing CHL-1 and non-expressing MIA-PaCa-2 xenograft tumors. This evidence concerns the gene ERBB3 and neoplasm.